Population-based incidence of herpes zoster after introduction of a publicly funded varicella vaccination program
- PMID: 21939721
- DOI: 10.1016/j.vaccine.2011.09.024
Population-based incidence of herpes zoster after introduction of a publicly funded varicella vaccination program
Abstract
Background: Past varicella infection (chicken pox) may reactivate into herpes zoster (shingles). Varicella vaccination leads to a reduction in cases of varicella that may in turn increase herpes zoster rates due to reduction in the immune boosting effect of exposure to varicella zoster virus against varicella reactivation. We assessed the impact of childhood varicella vaccination in Ontario, Canada on zoster incidence and healthcare visits, and established baseline zoster rates prior to zoster vaccine introduction.
Methods: We used population-based, administrative databases to identify zoster incidence and healthcare use from April 1992 to March 2010.
Results: After routine varicella vaccination, zoster incidence rates decreased 29% for children aged 0-9 and changed minimally for other ages. Age-standardized rates of hospitalizations during the study period declined by 53%, while outpatient rates declined by 9%. The annual zoster incidence for those 60 or older was 740 per 100,000.
Conclusions: In the early post-varicella vaccination period, incidence rates of medically attended herpes zoster did not increase for the overall population and decreased moderately for children 9 years and younger, the age group targeted for varicella vaccination.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Similar articles
-
Modelling the impact of a combined varicella and zoster vaccination programme on the epidemiology of varicella zoster virus in England.Vaccine. 2011 Mar 16;29(13):2411-20. doi: 10.1016/j.vaccine.2011.01.037. Epub 2011 Jan 28. Vaccine. 2011. PMID: 21277405
-
Modelling the impact of varicella vaccination on varicella and zoster.Epidemiol Infect. 2010 Apr;138(4):469-81. doi: 10.1017/S0950268809990768. Epub 2009 Oct 2. Epidemiol Infect. 2010. PMID: 19796447
-
The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination.Pediatr Infect Dis J. 2009 Nov;28(11):954-9. doi: 10.1097/INF.0b013e3181a90b16. Pediatr Infect Dis J. 2009. PMID: 19536039
-
The effect of vaccination on the epidemiology of varicella zoster virus.J Infect. 2002 May;44(4):211-9. doi: 10.1053/jinf.2002.0988. J Infect. 2002. PMID: 12099726 Review.
-
The impact of the varicella vaccination program on herpes zoster epidemiology in the United States: a review.J Infect Dis. 2008 Mar 1;197 Suppl 2:S224-7. doi: 10.1086/522162. J Infect Dis. 2008. PMID: 18419401 Review.
Cited by
-
Varicella zoster virus vaccines: an update.Immunotargets Ther. 2019 Aug 6;8:15-28. doi: 10.2147/ITT.S176383. eCollection 2019. Immunotargets Ther. 2019. PMID: 31497569 Free PMC article.
-
Effectiveness and cost-effectiveness of vaccination against herpes zoster in Canada: a modelling study.CMAJ. 2019 Aug 26;191(34):E932-E939. doi: 10.1503/cmaj.190274. CMAJ. 2019. PMID: 31451524 Free PMC article.
-
Cost-effectiveness and public health impact of recombinant zoster vaccine versus no herpes zoster vaccination in selected populations of immunocompromised adults in Canada.BMC Health Serv Res. 2025 Apr 25;25(1):604. doi: 10.1186/s12913-025-12550-x. BMC Health Serv Res. 2025. PMID: 40281614 Free PMC article.
-
Cost-effectiveness of vaccination against herpes zoster.Hum Vaccin Immunother. 2014;10(7):2048-61. doi: 10.4161/hv.28670. Hum Vaccin Immunother. 2014. PMID: 25424815 Free PMC article. Review.
-
Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany.Eur J Health Econ. 2013 Dec;14(6):1015-26. doi: 10.1007/s10198-012-0452-1. Epub 2012 Dec 28. Eur J Health Econ. 2013. PMID: 23271349
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous